Impact of Drug Price Revisions and Competing Products on Pharmaceutical Sales
First written in FY2016-Q2. 17 of 20 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
47 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「In Japan, regular drug price reductions and the use of generic drugs are being promoted. In the United States, another key market for our Group, policies to control the prices of originator drugs (branded products) under the Inflation Reduction Act are being implemented, along with measures to promote the use of low-cost generic drugs and biosimilars.」
Continues to identify Japan's drug price reductions and promotion of generics, as well as U.S. price controls and the promotion of generics and biosimilars, as risks to pharmaceutical sales. - FY2023RestatedAnnual report
「In Japan, regular drug price reductions and the use of generic drugs are being promoted. In the United States, another key market for our Group, policies to control the prices of originator drugs (branded products) under the Inflation Reduction Act are being implemented, along with measures to promote the use of low-cost generic drugs and biosimilars.」
Continues to state healthcare cost-control measures, including Japan's drug price reductions and promotion of generics and the U.S. policy under the Inflation Reduction Act to control branded-drug prices. - FY2022RestatedAnnual report
「In Japan, the government has indicated a policy of optimizing healthcare costs to curb their continued increase, including regular drug price reductions and the promotion of generic drug use.」
Continues to identify Japan's drug price reductions and promotion of generics, as well as branded-product price reductions and biosimilar promotion in the United States, as risks related to healthcare cost-control measures. - FY2022-Q3RestatedAnnual report
「In Japan, sales increased through online information activities, including web-based seminars. In addition, generic drugs have been launched following the expiration of exclusivity for the indications of heart failure- and cirrhosis-related fluid retention in Japan, hyponatremia in the United States, and hyponatremia caused by syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Europe.」
States that, while the impact of generic drug launches continued, sales increased in Japan through online information activities. - FY2021RestatedAnnual report
「In Japan, the government has indicated a policy of optimizing healthcare costs to curb their continued increase, including regular drug price reductions and the promotion of generic drug use.」
Continues to identify Japan's drug price reductions and promotion of generics, as well as price reductions for branded products and the promotion of generic and biosimilar use in the United States, as risks to pharmaceutical sales. - FY2021-Q1RestatedAnnual report
「In Japan, prescriptions continued to increase for the treatment of fluid retention associated with heart failure and cirrhosis and for autosomal dominant polycystic kidney disease (ADPKD), supported by the use of online information activities and other measures. However, revenue was roughly unchanged year on year due to the impact of the substantial drug price reduction resulting from market expansion repricing in the April 2020 drug price revision.」
Continues to state that, while prescriptions of Samsca continued to increase, the substantial drug price reduction resulting from the drug price revision affected revenue. - FY2020RestatedAnnual report
「In Japan, prescriptions for the treatment of autosomal dominant polycystic kidney disease (ADPKD) continued to increase, while the substantial drug price reduction resulting from market expansion repricing in the April drug price revision and prescriptions for the treatment of cardiac edema were affected by a decline in the number of hospitalized patients due to the spread of COVID-19.」
Explains that, while prescriptions of Samsca increased, sales were affected by a substantial drug price reduction resulting from the drug price revision and a decline in the number of hospitalized patients. - FY2020-Q3RestatedAnnual report
「In Japan, prescriptions continued to increase both for the treatment of cardiac and hepatic edema and for autosomal dominant polycystic kidney disease (ADPKD), a rare kidney disease. However, affected by a drug price reduction resulting from market expansion repricing in the April drug price revision, revenue decreased 1.6% year on year to ¥66,152 million.」
Continues to state that, while prescriptions of Samsca continued to increase, drug price reductions resulting from market expansion repricing affected revenue. - FY2020-Q2RestatedAnnual report
「In Japan, although Samsca was affected by a drug price reduction resulting from market expansion repricing in the April drug price revision, prescriptions continued to increase both as a treatment for cardiac and hepatic edema and as a treatment for autosomal dominant polycystic kidney disease (ADPKD), a rare kidney disease.」
Continues to state that drug price reductions affected Samsca sales, while explaining that prescriptions increased. - FY2019RestatedAnnual report
「In Japan, the Ministry of Health, Labour and Welfare has indicated a policy of curbing the growth of medical costs to contain their continued increase, and measures including regular drug price reductions and the promotion of generic drug use are progressing.」
Continues to identify Japan's drug price reductions and promotion of generics, as well as downward price pressure on branded products in the United States, as risks to pharmaceutical sales. - FY2018WorsenedAnnual report
「Under the Second Medium-Term Management Plan, the external environment changed substantially from the assumptions made when the plan was formulated, including fundamental reforms to Japan's drug pricing system and measures to promote the use of generic drugs in Japan and Europe. As a result, revenue fell short of the target, mainly for long-listed products and new domestic drugs.」
Explains that reforms to the drug pricing system and measures to promote generic drug use were explicit external environmental changes exceeding the assumptions made when the plan was formulated, and were factors behind the failure to achieve the revenue target. - FY2018-Q3RestatedAnnual report
「Lonsurf sales declined due to the impact of external factors, including competition.」
Continues to state that external factors, including competition, have affected pharmaceutical sales. - FY2018-Q2RestatedAnnual report
「In the gastrointestinal field, Takecab tablets, an acid-related disease treatment co-promoted with Takeda Pharmaceutical Company Limited, were affected by a drug price reduction under special market expansion repricing in the latest drug price revision, but prescriptions continued to increase from the previous fiscal year.」
Continues to state the risk that price reductions resulting from drug price revisions will affect pharmaceutical sales. - FY2017WorsenedAnnual report
「In the United States, another key market for our Group, the use of low-cost generic drugs is being promoted, while branded products face downward price pressure due to strong demands from the federal and state governments and managed-care organizations. The use of low-cost generic drugs is also progressing, and future developments in healthcare cost policies may have a material impact on our Group's operating results and financial position.」
States that, in addition to drug price reductions and the promotion of generics in Japan, downward price pressure on branded products has intensified in the United States. - FY2017-Q3RestatedAnnual report
「Abraxane was affected by the application of market expansion re-pricing, but sales increased slightly year on year.」
Continues to state that the drug pricing system, including market expansion repricing, has affected pharmaceutical sales. - FY2017-Q2RestatedAnnual report
「Abraxane was affected by the application of market expansion re-pricing, but sales increased slightly year on year.」
Continues to state that drug price revisions and market expansion repricing have affected sales of pharmaceuticals including Abilify and Abraxane. - FY2017-Q1RestatedAnnual report
「Abilify sales declined year on year due to the impact of the market expansion re-pricing applied in the April 2016 drug price revision.」
The impact of the drug price revision and market expansion re-pricing on sales of Abilify, Abraxane and other products continues to be documented. - FY2016RestatedAnnual report
「In Japan, the Ministry of Health, Labour and Welfare has indicated a policy of curbing the growth of medical costs to contain their continued increase, and measures including regular drug price reductions and the promotion of generic drug use are progressing.」
The impact of drug price reductions, generic drugs and competing products on pharmaceutical sales continues to be documented as a significant business risk. - FY2016-Q3RestatedAnnual report
「Global sales of the antineoplastic agent TS-1 declined year on year due to the impact of drug price revisions and competing products in Japan, among other factors.」
The impact of drug price revisions and competing products on sales of TS-1, UFT, Uzel and other products continues to be documented. - FY2016-Q2First statedAnnual report
「Global sales of the antineoplastic agent TS-1 declined year on year due to the impact of drug price revisions and competing products in Japan, among other factors.」
The decline in sales due to drug price revisions, the promotion of generic drug use and competing products is being explained for multiple products.